Cochrane · systematic review · CD008415
Post‐surgical chemotherapy versus surgery alone for resectable gastric cancer
Diaz‐Nieto, R, Orti‐Rodríguez, R, Winslet, M · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 8 · 80%High 2 · 20%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Post‐surgical chemotherapy compared to surgery alone for resectable gastric cancer
Population: patients with resectable gastric cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall Survival (OS) Post‐surgical chemotherapy vs surgery alone | HR 0.85 [0.8, 0.9] | 34 studies · 7523 participants | High |
Disease Free Survival Post‐surgical chemotherapy vs surgery alone | HR 0.79 [0.72, 0.87] | 15 studies · 4133 participants | High |
Subgroup analysis for resectable gastric cancer
Population: patients with resectable gastric cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Chemobased OS ‐ 5‐FU based chemotherapy OS | HR 0.88 [0.83, 0.94] | 28 studies · 5694 participants | Moderate |
Chemobased OS ‐ Platinum‐based chemotherapy OS | HR 0.9 [0.81, 1] | 9 studies · 1504 participants | Moderate |
Chemobased DFS ‐ 5‐FU based chemotherapy DFS | HR 0.86 [0.78, 0.95] | 13 studies · 2944 participants | Moderate |
Chemobased DFS ‐ Platinum‐based chemotherapy DFS | HR 0.89 [0.75, 1.06] | 4 studies · 969 participants | Moderate |
Subgroup analysis for resectable gastric cancer
Population: patients with resectable gastric cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Stage OS analysis ‐ T1/2 OS | HR 0.86 [0.71, 1.05] | 5 studies · 1146 participants | Moderate |
Stage OS analysis ‐ T3/4 OS | HR 0.66 [0.41, 1.08] | 4 studies · 1008 participants | Moderate |
Lymph node mets analysis ‐ N‐ OS | HR 0.74 [0.41, 1.33] | 2 studies · 402 participants | Moderate |
Lymph node mets analysis ‐ N+ OS | HR 0.78 [0.67, 0.91] | 4 studies · 877 participants | Moderate |